Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 17/20 | 0.81 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3910198 | 0.94 | OPRK1 (0.86) | OPRK1NPC1RAB9ALMNAMAPT | |
| SCHEMBL3906004 | 0.89 | OPRK1 (0.79) | OPRK1NPC1RAB9A | |
| SCHEMBL14793427 | 0.87 | OPRK1 (1.00) | OPRK1LMNAMAPTNPSR1 | |
| SCHEMBL3913035 | 0.86 | OPRK1 (0.80) | OPRK1NPC1RAB9A | |
| SCHEMBL14793430 | 0.86 | OPRK1 (0.84) | OPRK1LMNAMAPTNPSR1TSHR | |
| SCHEMBL16302919 | 0.86 | OPRK1 (0.84) | OPRK1 | |
| SCHEMBL3910599 | 0.84 | ALDH1A1 (0.60) | OPRK1NPC1RAB9ALMNATSHR | |
| SCHEMBL18057330 | 0.80 | OPRK1 (0.81) | OPRK1NPC1RAB9A | |
| SCHEMBL16302935 | 0.80 | OPRK1 (1.00) | OPRK1NPC1RAB9ALMNAMAPT | |
| SCHEMBL10432177 | 0.80 | ALDH1A1 (0.74) | OPRK1NPC1RAB9ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7563905-B2 | Triazole derivatives and method of using the same to treat HIV infections | WYETH (US) | 2009-07-21 | — | — | US | claimed |
| WO-2005090320-A2 | TRIAZOLE DERIVATIVES AND METHOD OF USING THE SAME TO TREAT HIV INFECTIONS | WYETH (US) | 2005-09-29 | — | — | WO | claimed |
| US-20050209287-A1 | Triazole derivatives and method of using the same to treat HIV infections | WYETH | 2005-09-22 | — | — | US | claimed |
| US-7563905-B2 | Triazole derivatives and method of using the same to treat HIV infections | WYETH (US) | 2009-07-21 | — | — | US | disclosed |
| WO-2005090320-A2 | TRIAZOLE DERIVATIVES AND METHOD OF USING THE SAME TO TREAT HIV INFECTIONS | WYETH (US) | 2005-09-29 | — | — | WO | disclosed |
| US-20050209287-A1 | Triazole derivatives and method of using the same to treat HIV infections | WYETH | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209287-A1 | Triazole derivatives and method of using the same to treat HIV infections | CYP3A43, XDH, AKR1C3 | OPRK1 660/4885NPC1 509/4885RAB9A 4291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.